- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04900662
Patient Satisfaction and Visual Function Following Implantation of Trifocals or Extended Range of Vision Intraocular Lenses
25. januar 2022 oppdatert av: Dr. Sherif R El-Defrawy, Queen's University
Patient Satisfaction and Visual Function Following Implantation of Trifocals or Extended
Cataract surgery is a fast evolving refractive procedure, which aims to restore vision.
The majority of intraocular lens (IOL) implants following cataract surgery are monofocal IOLs, which have been designed to improve distance vision by replacing the lens diopter power with a single focal point.
Monofocal IOLs have been associated with very few complications related to the material or the technology.
However, after the surgery patients are spectacle dependent for near and intermediate tasks.
This, in turn, has decreased the patient's post-operative satisfaction and quality of life.
Multifocal intraocular lenses (IOLs) were introduced into the market in the 1980s.
This type of IOLs provides clear distance and near vision, which affects the quality of life and visual expectations of the patients who receive them.
Studies have indicated higher levels of patient's satisfaction with regards to distance and near vision after the implantation of multifocal lenses.
With Multifocal IOLs; however, patients are still spectacle dependent for intermediate tasks such as computer work.
The recent development of trifocal IOLs has been found to provide optimal near, intermediate, and distance visual performances; decrease spectacle dependence; and increase patient satisfaction.AcrySof®IQ PanOptix™ (PanOptix) was introduced into the market in 2015 with a design that allows the IOL to provide optimal near, intermediate, and distance visual performances; decrease spectacle dependence; and increase patient satisfaction.
Despite the benefits of corrected visual acuity at multiple distances, multifocal and/or trifocal IOLs are associated with certain disadvantages, including contrast sensitivity loss, dysphotopsia, halos and glare, which account for over a third of the justifications used for IOL model replacement.
Dysphotopsia is the result of light reflecting off the intraocular lens (IOL) onto the retina which causes a variety of visual symptoms that are expressed in a positive or a negative form.
Positive dysphotopsia refers to bright artifacts that are noticed in only certain lighting conditions, such as glare and halos.
Negative dysphotopsia refers to the formation of a barrier, which prevents light from reaching the retina.
The result of the negative form of dysphotopsia is the formation of shadows that are often in the temporal visual field.
In 2014, the extended range of vision TECNIS Symfony®IOL (Symfony), with new optical technology using a proprietary achromatic diffractive echelette design, received a CE Mark.
However, it was not until 2016 that this IOL became the first extended depth of focus (EDF) IOL to gain approval by the U.S. Food and Drug Administration.
This new optical technology corrects the corneal chromatic aberration for enhanced contrast sensitivity, generating a continuous vision for distance through intermediate into near with low incidence of halos and glare.
Despite the benefits of EDF IOLs, Monaco et al. conducted a study in Italy and indicated that both PanOptix and Symfony IOLs seemed to be good options for patients with intermediate-vision requirements, whereas the PanOptix IOL may be better for patients with near-vision requirements.
A few studies in the literature have evaluated the performance of the PanOptix and Symfony IOLs in Europe.
Our current study would add great value to the literature since to the best of our knowledge; this is the first study to address the same IOLs in North America.
Cataract surgery expectations are continuously rising, and in an effort to maximize patient satisfaction post-operatively, the appropriateness of a patient for a particular IOL implantation should be evaluated carefully during the pre-operative assessment.
Therefore, further research is warranted to evaluate patient satisfaction with both PanOptix and Symfony IOLs.
The purpose of this study is to compare the visual outcomes and the subjective satisfaction results between patients implanted with PanOptix and Symfony IOLs.
Studieoversikt
Status
Rekruttering
Forhold
Studietype
Observasjonsmessig
Registrering (Forventet)
480
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 3A9
- Rekruttering
- Kensington Eye Institute
-
Ta kontakt med:
- Mano Chandrakumar
- Telefonnummer: 6472050493
- E-post: mchandrakumar@KensingtonHealth.org
-
Hovedetterforsker:
- Sherif El-Defrawy, MD/PhD.
-
Underetterforsker:
- Matt Schlenker, MD/MSc.
-
Underetterforsker:
- Marko Popovic, MD
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Sannsynlighetsprøve
Studiepopulasjon
Study population is patients receiving cataract surgery at KEI. Sampling is consecutive.
No limitation based on gender or sex.
Beskrivelse
Inclusion Criteria:
- any patient receiving cataract surgery at KEI who is able and willing to participate over 18 years old.
Exclusion Criteria:
- less than 18, not receiving cataract surgery at KEI, not able or willing to participate
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
patient burden from preoperative fasting
Tidsramme: 2019-2021
|
A questionnaire will be used to assess.
|
2019-2021
|
incidence of aspiration or cancellation of surgery because of preoperative fasting violation
Tidsramme: 2019-2021
|
A questionnaire will be used to assess.
|
2019-2021
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- de Medeiros AL, de Araujo Rolim AG, Motta AFP, Ventura BV, Vilar C, Chaves MAPD, Carricondo PC, Hida WT. Comparison of visual outcomes after bilateral implantation of a diffractive trifocal intraocular lens and blended implantation of an extended depth of focus intraocular lens with a diffractive bifocal intraocular lens. Clin Ophthalmol. 2017 Oct 26;11:1911-1916. doi: 10.2147/OPTH.S145945. eCollection 2017.
- McAlinden C, Pesudovs K, Moore JE. The development of an instrument to measure quality of vision: the Quality of Vision (QoV) questionnaire. Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5537-45. doi: 10.1167/iovs.10-5341. Epub 2010 May 26.
- Calladine D, Evans JR, Shah S, Leyland M. Multifocal versus monofocal intraocular lenses after cataract extraction. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD003169. doi: 10.1002/14651858.CD003169.pub3.
- Weeber HA, Meijer ST, Piers PA. Extending the range of vision using diffractive intraocular lens technology. J Cataract Refract Surg. 2015 Dec;41(12):2746-54. doi: 10.1016/j.jcrs.2015.07.034.
- Santos BWL, Cançado JEP, Ferraz VAdS, Campos M. Evaluation of life quality of patients submitted to cataract surgery with implants of monofocal, bifocal and multifocal lenses. Revista Brasileira de Oftalmologia 2014;73:86-92
- Gundersen KG, Potvin R. Comparative visual performance with monofocal and multifocal intraocular lenses. Clin Ophthalmol. 2013;7:1979-85. doi: 10.2147/OPTH.S52922. Epub 2013 Oct 7.
- Cochener B, Vryghem J, Rozot P, Lesieur G, Chevalier JP, Henry JM, David T, Lesueur L, Gatinel D, Ganem C, Blanckaert J, Van Acker E, Heireman S, Ghekiere S. Clinical outcomes with a trifocal intraocular lens: a multicenter study. J Refract Surg. 2014 Nov;30(11):762-8. doi: 10.3928/1081597X-20141021-08.
- Attia MS, Auffarth GU, Khoramnia R, Linz K, Kretz FT. Near and intermediate reading performance of a diffractive trifocal intraocular lens using a reading desk. J Cataract Refract Surg. 2015 Dec;41(12):2707-14. doi: 10.1016/j.jcrs.2015.06.038.
- Escandon-Garcia S, Ribeiro FJ, McAlinden C, Queiros A, Gonzalez-Meijome JM. Through-Focus Vision Performance and Light Disturbances of 3 New Intraocular Lenses for Presbyopia Correction. J Ophthalmol. 2018 Jan 31;2018:6165493. doi: 10.1155/2018/6165493. eCollection 2018.
- AcrySof [product information]. Fort Worth TAL, Inc.; 2015
- de Vries NE, Webers CA, Montes-Mico R, Tahzib NG, Cheng YY, de Brabander J, Hendrikse F, Nuijts RM. Long-term follow-up of a multifocal apodized diffractive intraocular lens after cataract surgery. J Cataract Refract Surg. 2008 Sep;34(9):1476-82. doi: 10.1016/j.jcrs.2008.05.030.
- Kinard K, Jarstad A, Olson RJ. Correlation of visual quality with satisfaction and function in a normal cohort of pseudophakic patients. J Cataract Refract Surg. 2013 Apr;39(4):590-7. doi: 10.1016/j.jcrs.2012.11.023. Epub 2013 Feb 6.
- Monaco G, Gari M, Di Censo F, Poscia A, Ruggi G, Scialdone A. Visual performance after bilateral implantation of 2 new presbyopia-correcting intraocular lenses: Trifocal versus extended range of vision. J Cataract Refract Surg. 2017 Jun;43(6):737-747. doi: 10.1016/j.jcrs.2017.03.037.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
5. juli 2019
Primær fullføring (Faktiske)
31. august 2021
Studiet fullført (Forventet)
31. desember 2023
Datoer for studieregistrering
Først innsendt
6. oktober 2020
Først innsendt som oppfylte QC-kriteriene
21. mai 2021
Først lagt ut (Faktiske)
25. mai 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
4. februar 2022
Siste oppdatering sendt inn som oppfylte QC-kriteriene
25. januar 2022
Sist bekreftet
1. januar 2022
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- KEI20190718
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .